Caribou Biosciences halts CAR-T programs and seeks strategic alternatives after failing to secure funding
Caribou Biosciences, a CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, announced it will discontinue its two allogeneic CAR-T cell therapy programs and lay off staff after failing to secure funding for a pivotal lymphoma trial. The company's stock plunged 40% following the announcement as it explores strategic alternatives.
